Avacta Group (LSE:AVCT) has proposed a placing via an accelerated bookbuild and a subscription by four non-executive directors to raise approximately £12.5m at 68 pence per share. The company says the proceeds are intended to extend its cash runway into the second quarter of 2027 and to meet a Convertible Bond repayment due on 20 October.

What was announced

On 5 October 2026, AIM-quoted Avacta Group plc announced a proposed placing via an accelerated bookbuild and a subscription to raise approximately £12.5m before expenses. The fundraise is proposed, not completed: the bookbuild was expected to close at 7am on 6 October 2026, although it may close later by agreement between the bookrunner and the company, with a further announcement of the results to follow. Avacta stated that "Neither the Placing nor the Subscription have been underwritten."

The issue price of 68 pence represents a 5.6% discount to the closing mid-market price of 72 pence on 29 September 2026, the last trading day before the Capital Access Window. The placing targets approximately 17,413,352 new shares, raising about £11.8m, while the subscription covers 969,000 new shares, raising about £660,000. Together this amounts to approximately 18,382,352 new shares. The announcement does not state the new shares as a percentage of existing Share Capital and includes no retail offer.

Director participation

The subscription is being made by four non-executive directors: Richard Hughes, Non-Executive Chairman; Patrick Vink, Non-Executive Deputy Chairman; and David Bryant and Mats Blom, Non-Executive Directors. Their combined subscription is approximately £660,000 for 969,000 shares at the issue price. The individual split between the four is not set out in the information reviewed.

Use of proceeds

Avacta said it "currently has a cash runway into early Q1 2027". The fundraise is intended "to provide Working Capital to extend the Company's cash runway into Q2 2027", which the company said would further strengthen its partnering position and balance sheet. Of the proceeds, approximately £2.5m "will be used to satisfy the next quarterly Convertible Bond repayment due on 20 October 2026, in cash."

The remaining funds are earmarked for the company's pre|CISION platform. This includes continued development of AVA6103 (FAP-Exd), ongoing Phase 1b expansion cohorts for faridoxorubicin (AVA6000), and progress on AVA6207, a next-generation dual-payload programme designed to release two payloads through a single FAP cleavage event.

The raise follows Avacta's announcement on 16 September 2026 that it had achieved clinical proof of mechanism for AVA6103, its second clinical candidate. According to the company, the Phase 1 FOCUS-01 data showed a clean safety profile, including at a payload dose approximately 50% higher than the maximum tolerated dose of conventional exatecan, and pharmacokinetics closely aligned with the preclinical modelling. The board said these data "greatly increase the confidence of the Board" that preclinical results will translate into the clinic. Avacta anticipates first AVA6103 efficacy data in H1 2027 and AVA6207 candidate selection data in Q4 2026; these timelines are the company's own.

What to watch next

The immediate next step is the results announcement following the close of the bookbuild, which will confirm the final amount raised. The placing is conditional on, among other things, admission of the new shares, which is expected at 8:00am on 9 October 2026 on AIM. Other conditions include the placing agreement not being terminated and the Capital Access Window closing, with trading resuming, by admission. Beyond that, the 20 October convertible bond repayment and the company's stated clinical milestones are the next points of reference. Strand Hanson is nominated adviser, Zeus Capital broker and sole bookrunner, and Beech Hill Securities US placing agent.